TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02889302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373
Description: 24 weeks
Study: NCT04129021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution retinal imaging through adaptive optics
Description: The protocol consists of performing retinal imaging using full-field optical coherence tomography. The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution retinal imaging through holographic systems
Description: The protocol consists of performing retinal imaging using a laser Doppler holography. For each system, the participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
Study: NCT03942653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Goserelin Acetate, SQ, Q4W
Study: NCT02889302

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 weeks
Study: NCT03942653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, IV, Q3W
Study: NCT00835042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets
Description: 1 x 15/25 mg
Study: NCT04536792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-946
Description: AG-946, oral encapsulated coated-granules or tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-946
Description: AG-946, oral encapsulated coated-granules or tablets.
Study: NCT00835042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UNIRETIC® 15/25 mg tablets
Description: 1 x 15/25 mg
Study: NCT02088554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model 400 aortic valve bioprosthesis
Study: NCT04536792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-946
Description: AG-946, oral encapsulated coated-granules or tablets.
Study: NCT03100461

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I2
Description: A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I2
Description: A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I2
Description: A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Standard of care approach that will provide basic information on CRC screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Standard of care approach that will provide basic information on CRC screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Standard of care approach that will provide basic information on CRC screening.
Study: NCT04536792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-946 Matched Placebo
Description: AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-946 Matched Placebo
Description: AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
Study: NCT04150497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART22
Description: Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLLS52
Description: A monoclonal antibody that recognizes a CD52 antigen
Study: NCT02196207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eloctate ITI plus Emicizumab
Description: Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion plus Emicizumab (1.5 mg/kg) weekly by subcutaneous injection will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eloctate ITI
Description: Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
Study: NCT02942927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reduction
Description: Systematic approach to reduction in polypharmacy.
Study: NCT02851940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation
Description: Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline Infusion
Description: Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
Study: NCT01162928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutriflex Omega special + Oxepa
Description: 3-chamber-bag combined with enteral nutrition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutriflex Lipid special + Pulmocare
Description: 3-chamber-bag combined with enteral nutrition
Study: NCT04064177

Intervention type: DEVICE
Intervention: NICAS cardiac output monitor
Description: Non-invasive continuous cardiac output monitoring device using total body bioimpedance.

Intervention type: DEVICE
Intervention: NICAS cardiac output monitor
Description: Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
Study: NCT03102112

Intervention type: OTHER
Intervention: MRI examination
Description: A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
Study: NCT00675259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days \[1 cycle\] for 5 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 2 IV on days 1, 8, and 15
Study: NCT01189682

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tegaderm, Tegaderm HP, Tegaderm CHG
Description: dressings on catheters

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm, Tegaderm HP, Tegaderm CHG
Description: dressings on catheters
Study: NCT00675259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 100 mg/M2 IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
Study: NCT04205253

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography imaging
Description: This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography imaging
Description: This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.
Study: NCT06637046

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic procedures
Description: A 30-gauge 1-inch needle was inserted adjacent to, but not within, the CFN. The infiltrate was delivered at the level of the fibular neck just proximal to where the CPN coursed beneath the deep fascia of the peroneus longus. This was immediately adjacent to the first known anatomical site of compression of the CPN. 0.3cc of the drug was delivered.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic procedures
Description: A 30-gauge 1-inch needle was inserted adjacent to, but not within, the CFN. The infiltrate was delivered at the level of the fibular neck just proximal to where the CPN coursed beneath the deep fascia of the peroneus longus. This was immediately adjacent to the first known anatomical site of compression of the CPN. 0.3cc of the drug was delivered.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl
Description: This study compares the vasodilatory effects of lidocaine to papaverine after diagnostic infiltration of the Common Peroneal Nerve in patients with demonstrated motor weakness of the EHL (extensor hallucis longus).
Study: NCT02229331

Intervention type: OTHER
Intervention: Gait analysis
Study: NCT06637046

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl
Description: This study compares the vasodilatory effects of lidocaine to papaverine after diagnostic infiltration of the Common Peroneal Nerve in patients with demonstrated motor weakness of the EHL (extensor hallucis longus).
Study: NCT06644677

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV integration
Description: Collect late-stage cervical cancer (Stage IIIB and beyond) and post-treatment recurrence and metastasis specimens (TCT, tissue) associated with HPV infection. Utilize third-generation nanopore technology to detect the integration sites of HPV DNA based on the principle of probe hybridization capture. Obtain information on HPV integration and hot spot genes in the samples. By analyzing the integration of HPV in primary and recurrent/metastatic tissues, identify insertions and gene alterations associated with recurrence/metastasis, and develop a predictive formula.
Study: NCT00851344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK835726 (10mg)
Description: GSK835726 (10mg) tablet
Study: NCT01189682

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm, Tegaderm HP, Tegaderm CHG
Description: dressings on catheters
Study: NCT00607477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: 2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: 25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
Study: NCT02518698

Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
Study: NCT04577703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT053PTSA
Description: CT053PTSA will be administered daily in fasting state
Study: NCT00248235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT00851344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK835726 (50mg)
Description: GSK835726 (50mg) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK835726 (100mg)
Description: GSK835726 (100mg) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine (10mg)
Description: Cetirizine (10mg) tablet as positive control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match active
Study: NCT02595996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
Study: NCT02951338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROPEL program
Description: The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group aerobic exercise
Description: Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites.
Study: NCT01154829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amisulpride
Description: Individually dosed, according to symptoms, for a period of 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: Individually dosed, according to symptoms, for a period of 6 weeks
Study: NCT03012724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H7-Coil
Description: Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H1-Coil
Description: Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
Study: NCT02284360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APOSEC™ for cutaneous use
Description: On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APOSEC™ for cutaneous use
Description: On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure.
Study: NCT01882348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CEASE Intervention
Description: The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)-including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
Study: NCT00468468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor
Description: computer based education and support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor
Description: computer based education and support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor
Description: computer based education and support
Study: NCT05912660

Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Aortic Valve Replacement (surgically or TAVI)

Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Aortic Valve Replacement (surgically or TAVI)
Study: NCT04143087

Intervention type: DRUG
Intervention: withdrawal TKIs or halve TKIs
Description: Stop TKIs or treated by half TKIs

Intervention type: DRUG
Intervention: withdrawal TKIs or halve TKIs
Description: Stop TKIs or treated by half TKIs
Study: NCT02994134

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise.
Description: Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise.
Description: High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
Study: NCT05350306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chincup
Description: Patients will receive an individual fabricated bonded bite block and occipital chincup. A 400-500g/side retroactive force will be applied in the direction of the condyles. Patients or panthers will be instructed to wear the appliance /14-16/ hours a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The changes in condyle-mandibular volumes and superficial areas and relative positions of the condyles and glenoid fossa will be calculated after 16 months of observation.
Study: NCT00805701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: avodart
Description: 0.5 avodart once daily for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03989765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programme to reduce involuntary treatment episodes
Description: See description of trial arms
Study: NCT03169686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and Behavioral Intervention
Description: Participants who allocate to the intervention group will receive regular smoking cessation related information by professional team.
Study: NCT02165371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sinovuyo Caring Families Programme
Description: Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa.
Study: NCT01869881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anplag(Sarpogrelate)
Description: Sarpogrelate 100mg 2 tablets, bid, 400mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100mg 2 tablets, bid, 400mg/day
Study: NCT02402829

Intervention type: PROCEDURE
Intervention: Peripheral Vein Blood draw
Description: Drawing blood through a peripheral vein in the arm.